Charles River Laboratories International (CRL) Receiving Favorable News Coverage, Accern Reports

Media headlines about Charles River Laboratories International (NYSE:CRL) have trended positive on Wednesday, according to Accern. The research group rates the sentiment of media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Charles River Laboratories International earned a daily sentiment score of 0.27 on Accern’s scale. Accern also assigned news stories about the medical research company an impact score of 46.7092274751785 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

These are some of the media headlines that may have impacted Accern Sentiment Analysis’s scoring:

CRL has been the subject of several research analyst reports. Robert W. Baird reissued a “buy” rating and issued a $114.00 price objective on shares of Charles River Laboratories International in a report on Friday, September 1st. Bank of America decreased their price target on Charles River Laboratories International from $117.00 to $115.00 and set a “buy” rating for the company in a report on Friday, November 10th. Zacks Investment Research raised Charles River Laboratories International from a “hold” rating to a “buy” rating and set a $129.00 price target for the company in a report on Tuesday, October 24th. Royal Bank Of Canada began coverage on Charles River Laboratories International in a report on Tuesday, September 19th. They set a “sector perform” rating and a $110.00 price target for the company. Finally, Credit Suisse Group reaffirmed a “neutral” rating and set a $112.00 price target (up from $95.00) on shares of Charles River Laboratories International in a report on Monday, October 16th. Seven investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. Charles River Laboratories International has an average rating of “Buy” and a consensus price target of $106.63.

Charles River Laboratories International (NYSE:CRL) traded up $0.66 during trading on Wednesday, reaching $102.48. The company’s stock had a trading volume of 218,270 shares, compared to its average volume of 378,950. Charles River Laboratories International has a 12 month low of $72.06 and a 12 month high of $119.05. The company has a current ratio of 1.88, a quick ratio of 1.62 and a debt-to-equity ratio of 1.13. The firm has a market capitalization of $4,834.19, a P/E ratio of 20.05, a P/E/G ratio of 1.63 and a beta of 0.89.

Charles River Laboratories International (NYSE:CRL) last released its earnings results on Thursday, November 9th. The medical research company reported $1.30 EPS for the quarter, beating analysts’ consensus estimates of $1.22 by $0.08. Charles River Laboratories International had a return on equity of 26.58% and a net margin of 10.72%. The company had revenue of $464.23 million during the quarter, compared to the consensus estimate of $458.93 million. During the same quarter last year, the company earned $1.18 earnings per share. Charles River Laboratories International’s quarterly revenue was up 9.0% compared to the same quarter last year. equities analysts anticipate that Charles River Laboratories International will post 5.13 EPS for the current fiscal year.

In other news, insider Bradley Nixon Scharfe sold 1,000,000 shares of the firm’s stock in a transaction on Friday, November 10th. The stock was sold at an average price of $0.27, for a total value of $270,000.00. Also, insider Davide Molho sold 6,165 shares of the firm’s stock in a transaction on Thursday, October 5th. The shares were sold at an average price of $110.00, for a total value of $678,150.00. The disclosure for this sale can be found here. In the last three months, insiders acquired 10,500 shares of company stock valued at $2,885. 2.20% of the stock is owned by corporate insiders.

TRADEMARK VIOLATION WARNING: This piece was originally posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this piece on another domain, it was stolen and republished in violation of United States & international trademark & copyright law. The correct version of this piece can be accessed at https://www.chaffeybreeze.com/2017/12/07/charles-river-laboratories-international-crl-receiving-favorable-news-coverage-accern-reports.html.

About Charles River Laboratories International

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Insider Buying and Selling by Quarter for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply